CA-AKTANA,-INC.
5.3.2024 13:01:34 CET | Business Wire | Press release
Aktana, Inc., the leader in intelligent customer engagement for global life sciences and the medical industry, today announced the availability of “Aktana for MedTech,” a set of tools designed to optimize field representative execution, account coordination and medical education programs with AI-powered insights and guidance.
The solution includes Aktana Copilot Mobile for MedTech, an interactive digital assistant that optimizes the execution of sales and marketing strategies across field commercial teams via mobile devices, delivering true omnichannel performance and impact.
“HCPs have overwhelmingly expressed their desire to leverage multiple digital channels to conduct their own research, interact with colleagues and engage with medical company representatives," said John Vitalie, CEO of Aktana. “However, less than 20% of MedTech companies are using advanced omnichannel capabilities. Those doing so are outpacing the industry in revenue by 2x.”
“Aktana for MedTech takes omnichannel to a completely new level by allowing medical device companies to plan and manage their interactions with HCPs through AI-guided intelligence all the way from pre-launch through to face-to-face meetings in the field to follow-up. At the same time, Aktana Copilot Mobile for MedTech captures real-time field reaction data, improving intelligence in real-time with every HCP interaction,” Vitalie continued.
Aktana for MedTech is comprised of Aktana’s world-class open platform, Field Orchestrator, Omnichannel Orchestrator, Analytics Activator, as well as Copilot Mobile. The tools use real-time, intelligence-driven nudges to field teams to simplify call planning and drive more personalized and coordinated activities, ultimately enhancing the quality of interactions with HCPs. Specifically, Aktana for MedTech:
- Allows medical technology companies to simplify scheduling, manage stock, optimize inventory utilization and streamline procurement processes with AI-powered omnichannel orchestration.
- Predicts product thresholds with AI-driven identification of critical account-level product volume changes, combined with dynamic actionable suggestions, to increase sales and decrease costs.
- Delivers medical education content far more effectively with dynamic actionable suggestions to ensure HCPs are getting the best information at the right time to better serve patients.
Concurring with research regarding physician preferences, Dr. Adil Ajuied, a knee surgeon at Guy's and St Thomas' NHS Foundation Trust and the Fortius Clinic London, says, "Being able to streamline the appointment scheduling process by analyzing my availability, preferences, and historical engagement patterns could ensure that meetings are scheduled at optimal times, minimizing disruptions to my clinical responsibilities, and allowing for more focused discussions."
Aktana for MedTech is CRM-agnostic and can integrate with all data sources. The set of tools is modular and can be deployed individually or combined with any of Aktana’s products. Aktana for MedTech is available immediately.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for global life sciences and the medical industry. By ensuring that every customer experience is tailored to individual preferences and needs, we help life science companies strengthen their relationships with healthcare providers to inspire better patient care. Aktana transforms the commercial engagement model to make each interaction more effective with proprietary blended-AI and mobile intelligence. Today, commercial and medical teams from more than 350 brands use Aktana’s next generation-AI complete orchestration to deliver personalized omnichannel engagement at scale. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305334832/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom